Category: Biotech
-
Longevity in the Age of Depopulation
If there’s one thing the biotech world loves, it’s a good hype cycle. We’ve seen it with CRISPR, stem cells, mRNA vaccines, and synthetic biology. But what if I told you that the next big biotech wave isn’t about curing cancer or building lab-grown burgers? No, the next frontier is far grander: solving aging itself.… Read more
-
Catching Big Pharma’s attention
Catching Big Pharma attention by Avi We focus on every detail so you can relax. Let us help you tell your story Calmly. Persuasively. Memorably 🎉 We take celebrating to the next level Read more
-
Biotech dreams & Startup nightmares
Let me take you back to a time when Avatar was breaking box office records, everyone was pretending to love quinoa, and I was an eager Master’s student interning at a small biotech startup. Let’s call it…BioHopeful Inc. (to spare feelings). The Product That Could Have Been a StarAt the core of BioHopeful’s ambitions was… Read more
-
Three Big Questions for Canada’s Innovation Ecosystem
A Reality Check on Our Productivity Crisis Canada’s innovation ecosystem feels like a group project where everyone’s working hard, but nobody’s quite sure who’s in charge. We’ve got the brains, the ambition, and a few gold stars on the global stage, but productivity numbers tell a different story. According to Stats Canada, labour productivity in… Read more
-
Promise and Challenges of Cell Therapy
Cell therapy isn’t as new as many believe. The concept of using cells as a therapeutic tool has been around for centuries. Blood transfusions, for instance, have been saving lives for centuries, and xenotransplantation, like using pig heart valves in humans, has been performed since the 1960s. These are early forms of ‘cell-based’ therapies that… Read more
-
Biotech’s 2024 Insane Megarounds: Rise of Giants or a Bubble in the Making?
There’s one thing biotech VC funding loves, it’s cycles—hype, bust, and everything in between. 2024, though? This year is bringing us something different, something big—Megarounds. And when I say big, I mean monumental. But before we get into the numbers, let’s talk about the journey that brought us here. Remember when the synthetic biology space… Read more
-
Drug Development Hacks for New Biotech Trailblazers
For more details, browse through the full blog post! Blog 2 – Phase appropriate material production by Avi You could choose anywhere between 3 to 10 million USD manufacturing strategies for your Phase I/II material. Keep in mind that faster and cheaper is not always better, but not by definition worse. Youri van Nuland /… Read more
-
Biotech VC world
Navigating biotech funding Shifting Landscape of Biotech Venture Capital: Challenges, Trends, and the Road Ahead. Key takeaways Venture Capital Expectations Investors want to see not just potential but a solid foundation of evidence that the technology is viable and that there is a market for it (bigger is better) Who you know matters In a… Read more